List of Excipients in Branded Drug PHENTERMINE HCL

Generic Drugs Containing PHENTERMINE HCL

Company	Ingredient	NDC	Excipient
Calvin Scott & Co Inc	phentermine hydrochloride	17224-905	CELLULOSE, MICROCRYSTALLINE
Calvin Scott & Co Inc	phentermine hydrochloride	17224-905	CROSCARMELLOSE SODIUM
Calvin Scott & Co Inc	phentermine hydrochloride	17224-905	LACTOSE MONOHYDRATE
Calvin Scott & Co Inc	phentermine hydrochloride	17224-905	MAGNESIUM STEARATE
Northwind Pharmaceuticals	phentermine hcl	51655-872	D&C YELLOW NO. 10
Northwind Pharmaceuticals	phentermine hcl	51655-872	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in PHENTERMINE HCL?

# Of NDCs	Excipient
1	ALCOHOL
1	ALUMINUM OXIDE
1	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	D&C RED NO. 28

Last updated: August 9, 2026

Phentermine HCl has limited API-level exclusivity and a mature generic market. The strongest commercial opportunities are excipient-led: lower-dose tablets, lactose-free products, orally disintegrating or taste-masked formats, improved manufacturability, and differentiated packaging for a controlled-substance product. The highest-probability strategy is a conventional immediate-release tablet or capsule using established excipients already supported in FDA-approved products. Novel modified-release systems face greater regulatory, abuse-liability, and clinical-risk barriers.

Phentermine HCl Excipient Strategy and Commercial Opportunities

What is the commercial position of phentermine HCl?

Phentermine hydrochloride is an oral sympathomimetic amine approved as a short-term adjunct to weight reduction in patients with obesity, alongside caloric restriction and behavioral modification. It is generally marketed as immediate-release tablets and capsules in strengths including 8 mg, 15 mg, 30 mg, and 37.5 mg, depending on the product.

Phentermine is a Schedule IV controlled substance in the United States under the Controlled Substances Act. The controlled-substance classification affects manufacturing controls, inventory management, serialization, distribution, diversion monitoring, and packaging strategy.[1]

The market is mature. Original compound and early product protection have expired, and generic manufacturers compete primarily on:

• price and supply reliability;
• dosage strengths;
• tablet and capsule availability;
• contract-manufacturing economics;
• pharmacy channel access;
• packaging and controlled-substance compliance;
• differentiated formulations that remain within a manageable FDA pathway.

Phentermine is not a biologic, so biosimilar risk does not apply. Competitive pressure comes from generic phentermine products, combination weight-management therapies, GLP-1 receptor agonists, and newer branded obesity medicines.

What excipients are used in phentermine HCl products?

Approved phentermine products typically use conventional oral solid-dose excipients. Exact compositions differ by manufacturer and dosage form, but common excipient categories include fillers, binders, disintegrants, lubricants, glidants, capsule-shell materials, and colorants.

Excipient category	Common examples	Primary function	Relevance to phentermine HCl
Diluent or filler	Lactose, microcrystalline cellulose, starch	Adjusts tablet mass and supports compression	Important for low-dose products such as 8 mg and 15 mg
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves granule and tablet strength	Useful where direct compression produces friability
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup	Supports immediate-release dissolution
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection friction	Excessive use can slow dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow	Relevant to content uniformity and high-speed compression
Capsule shell	Gelatin, hypromellose	Provides dosage-form enclosure	Enables color, shell, and vegetarian positioning
Colorant or opacifier	Titanium dioxide, iron oxides, approved dyes	Product identification and appearance	Important for branding and controlled-substance differentiation
Sweetener or taste modifier	Mannitol, sucralose, flavor systems	Supports orally disintegrating or chewable formats	Requires taste-masking and stability work

FDA’s Inactive Ingredient Database provides precedent for excipient use by route, dosage form, and maximum potency. It is the principal screening tool for selecting excipients that can support an abbreviated application without creating an unnecessary regulatory burden.[2]

What formulation properties matter most?

Phentermine HCl is a low-dose, potent active pharmaceutical ingredient. The principal formulation risks are content uniformity, segregation, powder flow, tablet weight variability, dissolution, and stability.

A low-dose tablet can contain less than 10% active ingredient by weight. Direct blending may create segregation if the API particle-size distribution, density, or electrostatic behavior differs materially from the excipient blend. A robust process may require:

• geometric dilution;
• ordered blending;
• wet granulation;
• dry granulation;
• particle-size control;
• low-shear lubrication;
• in-process blend uniformity testing.

The formulation should maintain rapid, reproducible immediate-release dissolution without excessive sensitivity to lubricant concentration or compression force.

What excipient strategy is most suitable for generic phentermine HCl?

The commercially strongest strategy is a platform based on well-established excipients and a conventional immediate-release dosage form.

Strategy 1: Lactose-based immediate-release tablet

Lactose is widely used in oral solid-dose products and can support low-cost formulation and acceptable tablet properties. It is suitable where the target population has no meaningful lactose-related positioning requirement.

Advantages include:

• low raw-material cost;
• broad supplier availability;
• established regulatory precedent;
• good compatibility with conventional tablet manufacture;
• compatibility with common starch-based disintegrant systems.

Risks include consumer demand for lactose-free products, possible formulation constraints in sensitive patients, and the need to control moisture and compression behavior.

Strategy 2: Lactose-free microcrystalline cellulose platform

A lactose-free formulation based on microcrystalline cellulose, mannitol, starch, or combinations of these excipients can target pharmacies and patients seeking alternative inactive ingredients.

Commercial benefits include:

• differentiated label positioning;
• access to lactose-avoidant customers;
• compatibility with direct compression;
• potential use across multiple strengths.

The main development issue is dose uniformity. Microcrystalline cellulose can improve compactability, but the developer must control API distribution across the blend. Colloidal silicon dioxide may improve flow, while crospovidone or croscarmellose sodium can maintain rapid disintegration.

Strategy 3: Low-dose tablet platform

The 8 mg and 15 mg strengths create a formulation opportunity because low-dose products place greater pressure on content uniformity and tablet size.

A scalable platform could use:

• a standardized premix of phentermine HCl and a portion of filler;
• a highly compactable diluent;
• a low-level disintegrant;
• controlled lubricant addition;
• separate compression targets for each strength.

This platform can reduce tooling changes and simplify scale-up. The business case is strongest when one blend design supports several strengths without creating unacceptable dissolution or weight-variation differences.

Strategy 4: Orally disintegrating tablet

An orally disintegrating tablet could provide differentiation through rapid disintegration, smaller tablet size, and reduced dependence on swallowing conventional tablets.

Potential excipients include mannitol, crospovidone, croscarmellose sodium, colloidal silicon dioxide, flavoring agents, and sweeteners. The active may require taste masking because phentermine salts can produce a bitter or medicinal taste.

Key development barriers include:

• taste masking without delaying drug release;
• friability;
• moisture sensitivity;
• packaging requirements;
• acceptable mouthfeel;
• dose uniformity at low drug loading;
• demonstration of bioequivalence under the applicable FDA standard.

An ODT is more commercially differentiated than a standard tablet, but the regulatory and technical burden is higher. A new ODT product may require an ANDA if it meets the relevant pharmaceutical-equivalence and bioequivalence requirements. A materially different delivery system may move toward a 505(b)(2) pathway under the Federal Food, Drug, and Cosmetic Act.[3]

Strategy 5: Capsule-shell differentiation

Capsules allow differentiation through shell composition, color, imprinting, and fill formulation. Hypromellose shells can support a vegetarian positioning, while gelatin remains the lower-cost conventional option.

Capsules may simplify development where powder flow and fill-weight control are favorable. They also permit color-based product identification, which is valuable for a controlled substance. The tradeoff is greater sensitivity to shell moisture, storage conditions, and capsule-filling performance.

What formulation patents could protect phentermine HCl products?

The original phentermine molecule and conventional immediate-release product concepts are commercially mature. New patent value would more likely arise from formulation or manufacturing claims than from the active ingredient itself.

Potential claim categories include:

1. A specific excipient ratio that produces defined dissolution or stability results.
2. A low-dose blend with improved content uniformity.
3. A taste-masked phentermine composition.
4. An orally disintegrating formulation with defined disintegration and dissolution parameters.
5. A multiparticulate or controlled-release system.
6. A manufacturing process that reduces segregation or improves yield.
7. A packaging system that limits moisture uptake or supports controlled-substance security.
8. A combination product involving phentermine and another active ingredient.

Patent strength depends on whether the claimed result is technically unexpected and whether the formulation can be designed around by substituting excipients or changing their concentrations. Broad claims covering routine use of lactose, microcrystalline cellulose, starch, or magnesium stearate are generally vulnerable to obviousness and written-description challenges.

A stronger formulation patent would tie the excipient system to measurable performance, such as:

• a narrow content-uniformity range;
• a defined dissolution profile;
• improved stability under accelerated conditions;
• a specific taste-masking performance;
• reduced tablet friability at a specified hardness;
• a manufacturing step that solves a documented segregation problem.

When does phentermine HCl lose exclusivity?

Phentermine HCl has no meaningful remaining small-molecule exclusivity barrier comparable to recently approved obesity therapies. Generic competition is established, and the commercial market is governed primarily by ANDA competition, manufacturing economics, and product availability.

Relevant regulatory protections are product-specific. FDA-listed patents and exclusivity information should be reviewed in the Orange Book for each listed reference product, dosage form, and strength.[4] Conventional phentermine products generally present a lower patent risk than branded GLP-1 medicines or newer combination obesity therapies.

Paragraph IV litigation risk may arise if a generic applicant certifies that a listed patent is invalid, unenforceable, or not infringed. The practical probability of a major Paragraph IV dispute is lower for an old, conventional phentermine immediate-release product than for a newer formulation with active patent listings.

What is the FDA regulatory pathway for a new phentermine formulation?

A conventional generic tablet or capsule normally proceeds through an ANDA under section 505(j). The applicant must establish pharmaceutical equivalence, bioequivalence, chemistry, manufacturing, and controls, along with compliance with controlled-substance requirements.[3]

A materially differentiated formulation may require a 505(b)(2) application. This pathway can be relevant to:

• orally disintegrating tablets;
• extended-release systems;
• novel taste-masked products;
• alternative dosage forms;
• products relying partly on FDA findings for a listed drug.

The regulatory route affects the commercial opportunity. An ANDA offers a faster path to a commodity market but limited differentiation. A 505(b)(2) product may obtain stronger product positioning and potentially more valuable intellectual property, but it requires more clinical, pharmacokinetic, formulation, and regulatory work.

What manufacturing and IP barriers affect commercial entry?

The most important barriers are operational rather than molecule-specific.

Manufacturing barriers

• Low-dose content uniformity.
• API segregation during transfer and compression.
• Control of lubrication to preserve dissolution.
• Tablet friability at small tablet sizes.
• Scale-up from laboratory blending to commercial equipment.
• Stability in high-humidity environments.
• Controlled-substance inventory and reconciliation.
• Secure storage, distribution, and recordkeeping.

Intellectual-property barriers

• Product-specific formulation claims.
• Taste-masking claims.
• Controlled-release claims.
• Combination-product claims.
• Manufacturing-process claims.
• Packaging or anti-counterfeiting claims.

A generic manufacturer can usually design around a narrow excipient patent by changing the filler, disintegrant, binder, granulation method, or capsule shell. Patent value rises when the claimed formulation is tied to a difficult-to-reproduce performance advantage.

Which commercial opportunities are most attractive?

Opportunity	Technical difficulty	Regulatory complexity	Differentiation	Commercial assessment
Standard 37.5 mg tablet	Low	Low	Low	Price-driven generic opportunity
Lactose-free tablet	Low to moderate	Low	Moderate	Practical line-extension opportunity
Multi-strength tablet platform	Moderate	Low	Moderate	Improves manufacturing efficiency
Vegetarian capsule	Low	Low	Low to moderate	Packaging and channel differentiation
Orally disintegrating tablet	Moderate to high	Moderate	High	Stronger product positioning
Taste-masked ODT	High	Moderate to high	High	Potential premium niche
Extended-release product	High	High	High	Greater clinical and regulatory risk
Combination therapy	High	High	High	Significant IP and clinical burden

The near-term opportunity is a lactose-free, low-dose, immediate-release tablet platform with reliable content uniformity and a clean excipient profile. The higher-value opportunity is an ODT or taste-masked product that provides a meaningful administration benefit without materially changing exposure.

How does phentermine compare with newer obesity drugs?

Phentermine has a low-cost, generic commercial profile. Newer agents such as semaglutide and tirzepatide have stronger patent estates, higher prices, injectable or specialized delivery requirements, and substantially larger clinical development programs.

Attribute	Phentermine HCl	Newer GLP-1 or GIP therapies
Product type	Small-molecule oral stimulant	Peptide-based therapy
Biosimilar risk	None	Relevant in the long term
Generic pathway	Established ANDA pathway	Generally more complex
Patent position	Mature and limited	Active composition, formulation, and use patents
Dosage form	Tablet or capsule	Often injectable, with some oral programs
Manufacturing barrier	Conventional oral solid dose	Higher biologic or peptide complexity
Commercial basis	Low cost and access	Clinical differentiation and branded pricing
Excipient opportunity	High relative to product price	More constrained by delivery and stability requirements

Phentermine cannot compete directly on efficacy claims with every newer obesity therapy. Its commercial value is based on affordability, oral administration, established prescribing familiarity, and formulation convenience.

What is the litigation and settlement outlook?

For conventional phentermine HCl products, litigation exposure is more likely to involve product liability, controlled-substance compliance, manufacturing quality, or ordinary generic patent disputes than a prolonged branded-generic settlement cycle.

A Paragraph IV settlement would matter only if an Orange Book-listed patent created a credible delayed-entry or licensed-entry right. For a mature immediate-release product, the more material business risks are:

• supply interruptions;
• FDA manufacturing observations;
• controlled-substance distribution restrictions;
• product recalls;
• pharmacy purchasing decisions;
• price erosion from multiple ANDA holders.

Key Takeaways

• Phentermine HCl is a mature generic small molecule with limited remaining API-level exclusivity.
• Excipients are the primary lever for product differentiation and manufacturing improvement.
• Lactose-free tablets, low-dose platforms, vegetarian capsules, and ODTs are the most credible opportunities.
• Content uniformity and blend segregation are the main technical risks in low-dose products.
• Conventional immediate-release products generally fit the ANDA pathway.
• Novel delivery systems may require a 505(b)(2) strategy and stronger supporting data.
• Formulation patents should claim measurable performance advantages rather than routine excipient combinations.
• Phentermine has no biosimilar exposure; its competitive threats are generic price erosion and newer obesity therapies.
• Controlled-substance compliance and supply reliability can have greater commercial impact than marginal excipient differences.

FAQs About Phentermine HCl Excipient Commercialization

Can phentermine HCl be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, starch, and other established fillers can support lactose-free tablets or capsules. The formulation must be optimized for blend uniformity, compressibility, dissolution, and stability.

Is an extended-release phentermine product commercially attractive?

It may offer meaningful differentiation, but the development burden is substantially higher than for an immediate-release generic. Pharmacokinetic behavior, dose dumping, abuse liability, food effects, and bioequivalence create significant regulatory risks.

What excipient is best for a phentermine ODT?

No single excipient is universally best. Mannitol can support mouthfeel, while crospovidone or croscarmellose sodium can promote rapid disintegration. The final selection depends on taste, tablet strength, moisture sensitivity, and dissolution performance.

Can a formulation patent extend phentermine exclusivity?

A new formulation patent cannot extend expired compound protection, but it may protect a separately developed product if the claims are valid, non-obvious, and tied to a distinct formulation or performance benefit.

Does phentermine HCl require special packaging?

Yes. As a Schedule IV controlled substance, phentermine products require controlled-substance compliance across manufacturing, storage, distribution, recordkeeping, and dispensing. Packaging also should support product identification, tamper resistance, and diversion control.

References

1. U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. U.S. Food and Drug Administration. (2024). DailyMed: Phentermine hydrochloride product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/